You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR PROVIGIL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PROVIGIL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00066170 ↗ Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy Completed Jazz Pharmaceuticals Phase 3 2003-04-01 This study will be conducted as a randomized, double blind, double-dummy, placebo-controlled, parallel-group trial in patients diagnosed with narcolepsy. Volunteers for this trial will be required to make 5 visits over up to 14 weeks to a participating expert physician practitioner for various sleep and narcolepsy evaluations and diaries will also be collected. Participants will take assigned medications during the course of the trial. Subjects will have a 25% probability of receiving placebo for both drugs (modafinil and Xyrem). All subject volunteers must meet criteria for narcolepsy and have evidence of daytime sleepiness. Patients will not incur any personal medical expenses due to participation in this trial. The sponsor is covering all visit costs not covered by insurance and there are some funds for patient expenses such as travel.
NCT00086281 ↗ Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Completed Jazz Pharmaceuticals Phase 4 2003-11-01 To study the effect of Xyrem (9 g), Xyrem (9 g) plus modafinil 200 mg administered the morning prior to Xyrem, positive control (zolpidem 10 mg), and placebo on the frequency and outcome of events of sleep-disordered breathing in patients with obstructive sleep apnea syndrome (OSAS).
NCT00107796 ↗ Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed Cephalon Phase 3 2004-10-01 Primary Objectives: The primary objectives of the study are to determine the effectiveness of PROVIGIL treatment, compared to placebo treatment, in children and adolescents with excessive sleepiness (ES) associated with narcolepsy, as assessed by: - mean sleep latency from the Multiple Sleep Latency Test (MSLT) (average of 4 naps performed at 0900, 1100, 1300, and 1500) at the last post-baseline observation (week 6 or early termination) - the Clinical Global Impression of Change (CGI-C) ratings for ES, at the last post-baseline observation (week 6 or early termination).
NCT00107809 ↗ Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome Completed Cephalon Phase 3 2004-10-01 The primary objectives of the study are to determine the effectiveness of PROVIGIL treatment, compared to placebo treatment, in children and adolescents with excessive sleepiness (ES) associated with obstructive sleep apnea/hypopnea syndrome (OSAHS), as assessed by: - mean sleep latency from the Multiple Sleep Latency Test (MSLT) (average of 4 naps performed at 0900, 1100, 1300, and 1500) at the last post baseline observation (week 6 or early termination) - the Clinical Global Impression of Change (CGI-C) ratings for ES, at the last post baseline observation (week 6 or early termination).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PROVIGIL

Condition Name

Condition Name for PROVIGIL
Intervention Trials
Fatigue 7
Schizophrenia 6
Cocaine Dependence 6
Narcolepsy 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PROVIGIL
Intervention Trials
Cocaine-Related Disorders 11
Sleepiness 10
Fatigue 10
Disorders of Excessive Somnolence 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PROVIGIL

Trials by Country

Trials by Country for PROVIGIL
Location Trials
United States 171
Canada 9
Germany 2
France 2
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PROVIGIL
Location Trials
California 14
New York 10
Pennsylvania 10
Texas 9
South Carolina 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PROVIGIL

Clinical Trial Phase

Clinical Trial Phase for PROVIGIL
Clinical Trial Phase Trials
Phase 4 16
Phase 3 12
Phase 2/Phase 3 1
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PROVIGIL
Clinical Trial Phase Trials
Completed 48
Terminated 7
Unknown status 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PROVIGIL

Sponsor Name

Sponsor Name for PROVIGIL
Sponsor Trials
National Institute on Drug Abuse (NIDA) 12
Cephalon 10
The University of Texas Health Science Center, Houston 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PROVIGIL
Sponsor Trials
Other 76
Industry 22
NIH 20
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.